[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603786":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":38,"collaborators":10,"id":42,"slug":10,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":10,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Grigore T. Popa University of Medicine and Pharmacy","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Hemodialysis group",null,"Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent.",{"label":13,"type":10,"description":14,"interventionNames":10},"Kidney transplant group","Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor.",{"label":16,"type":10,"description":17,"interventionNames":10},"General population osteoporosis\u002Fosteopenia","Men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Nada Akad, Dr.","CONTACT","0040742015245","akadnada@gmail.com",[25],{"facility":26,"status":27,"city":28,"state":10,"zip":10,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"University of Medicine and Pharmacy \"Grigore T. Popa\"","RECRUITING","Iași","Romania",{"type":31,"coordinates":32},"Point",[33,34],27.6,47.16667,{"lat":34,"lon":33},[37],{"name":20,"role":21,"phone":10,"phoneExt":10,"email":23},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Akad Nada","MD","100603786",false,"NCT07141043","Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","New Directions and Perspectives in the Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","Inclusion Criteria:\n\n1. HD group: Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent.\n2. KTR group: Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor.\n3. GPO group: men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.\n\nExclusion Criteria:\n\n1. HD group: Treatment with active bone therapies (excluding calcium and vitamin D); ongoing cancer treatment or recent history of malignancy, cirrhosis, recent major fractures, patients who have received transplants other than kidney, secondary causes of osteoporosis (other than CKD or transplant-related: primary hyperparathyroidism, hyperthyroidism, congenital bone disorders, sarcoidosis, severe bone trauma, malignant tumors, inflammatory bowel disease, endogenous Cushing syndrome, anti-estrogen\u002Fanti-androgen therapy, and anorexia nervosa), pregnancy and breast-feeding.\n2. KTR group: The same as for HD + return to dialysis + acute graft rejection.\n3. GPO group: The same as for HD + diabetes mellitus + prolonged glucocorticoid therapy (\\>7.5 mg Prednisone or equivalent for at least 3 months).",true,"ALL","20 Years","70 Years",{"count":53,"type":54},180,"ESTIMATED","OBSERVATIONAL","This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.",[58,59,60,61],"Hemodyalysis","Kidney Tansplant","Osteoporosis","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder",[63,60,64],"CKD-MBD","bone turnover markers","2025-08-18",{"date":67,"type":68},"2025-08-26","ACTUAL",{"date":70,"type":68},"2025-03-19",{"date":72,"type":54},"2027-06",{"name":5,"class":6},1]